Using decision analysis to evaluate the cost effectiveness of GP IIb/IIIa antagonists

Formulary

Volumn 34, Issue 6, 1999, Pages 515-522

  Cox, Emily R ^b   Armstrong, Edward P ^a   Motheral, Brenda R ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ALGORITHM; BLEEDING; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; EVALUATION; HUMAN; REVASCULARIZATION; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0033015472     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Freudenheim M. A new strain on the cost of health care. New York Times. April 9, 1999.
2. Zed PJ, Frighetto L, Sunderji R, Marra CA. Cost-effectiveness analysis of abciximab: A Canadian hospital perspective. Ann Pharmacother 1998;32:536-41.
3. Aristides M, Gliksman M, Rajan N, Davey P. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Heart 1998;79: 12-7.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-61.
5. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory angina: The CAPTURE study. Lancet 1997;349:1429-35.
6. Healey M, Deverka P. Panel 1: Methodological issues in pharmacoeconomic evaluations - clinical studies. Value in Health 1999;3:73-7.
7. Arnold RG, Kotsanos JG. Panel 3: Methodological issues in conducting pharmacoeconomic evaluations - retrospective and claims database studies. Value in Health 1999;3: 82-7.
8. Motheral BR, Fairman KA. The use of claims databases for outcomes research: Rationale, challenges, and strategies. Clin Ther 1997;19:346-66.
9. Hay J, Jackson J. Panel 2: Methodological issues in conducting pharmacoeconomic evaluations - modeling studies. Value in Health 1999;3:78-81.
10. Barr JT, Schumacher GE. Decision analysis and pharmacoeconomic evaluations. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics, 2nd ed. Cincinnati: Harvey Whitney Books, Co; 1996.
11. Basskin L. How to use decision analysis to solve pharmacoeconomic problems. Formulary 1997;32:619-28.
12. McElwee NE, Johnson ER. Potential economic impact of glycoprotein IIb/IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. Am J Cardiol 1997;80:39-43B.
13. Hull RD, Feldstein W, Stein PD, Pineo GF. Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med 1996;156:68-72.